India Pesticides Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 3 Jul 2026 | Fertilizers & Agrochemicals | Market Cap: ₹1.6K Cr
India Pesticides Limited aims to achieve INR 3,000 crores revenue by March 2031. India Pesticides expects revenue growth of 15-20% for the current financial year, maintaining earlier guidance.
From India Pesticides Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹140
Market Cap
₹1.6K Cr
P/E Ratio
15.0
How does India Pesticides Ltd rank in Fertilizers & Agrochemicals?
Compare India Pesticides Ltd against every Fertilizers & Agrochemicals company this quarter on revenue, margins and earnings-call signals.
India Pesticides Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹266 Cr, net profit ₹32 Cr.
Full financials →📊 Revenue & Sales Performance
- →India Pesticides Limited aims to achieve INR 3,000 crores revenue by March 2031.
- →The Shalvis subsidiary is expected to contribute around INR 1,000 crores by FY31.
- →Existing plants at Dewa Road, Sandila, and formulation facilities are projected to generate the remaining INR 2,000 crores.
- →For the current year, a revenue growth of 15% to 20% is expected.
- →Volume growth of about 30% was reported in Q4 FY26; continued growth anticipated with full utilization of new capacities.
- →New product introductions and backward integration to support stable EBITDA margins around 18%.
- →Strategic expansions underway, including capacity additions at Hamirpur and Shalvis facilities, expected to bolster volumes and revenues.
- →Market conditions, supply chain stability, and price adjustments are factored into growth outlook.
📈 Profitability & Margins
- →India Pesticides expects revenue growth of 15-20% for the current financial year, maintaining earlier guidance.
- →EBITDA margin is anticipated to remain steady at around 18%.
- →By FY31, the company targets INR 3,000 crores in revenue, with INR 1,000 crores expected from the Shalvis subsidiary and INR 2,000 crores from existing plants.
- →Capacity additions and backward integration efforts aim to sustain margins despite raw material cost pressures.
- →Continuous product pipeline expansion via R&D and increased utilization levels support long-term earnings growth.
- →Strategic investments, including INR 135 crores capex over FY27 (INR 45 crores standalone and INR 90 crores subsidiary), are expected to bolster future profitability.
- →Conserved funds and low leverage are intended to improve intrinsic investor value and enable funded expansions without excessive debt.
🏗️ Capital Expenditure Plans
- →India Pesticides has a capex budget of INR 45 crores for FY27 for the standalone entity and INR 90 crores for its 100% subsidiary, primarily funded through internal accruals.
- →Expansion plans include the Hamirpur facility development, with new technical blocks progressing as planned.
- →Capacity augmentation at Sandila site is mostly completed; only intermediate and technical grade product additions planned with some efficiency improvements.
- →Shalvis subsidiary is investing INR 90 crores in capex, including new plant operationalization expected to contribute to revenue by FY27-FY28.
- →Backward integration initiatives underway to improve supply chain stability and reduce import dependency.
- →The company focuses on strategic investments in product portfolio enhancement, manufacturing capabilities, and backward integration.
- →Capital work-in-progress of around INR 68 crores mainly attributed to Shalvis subsidiary with capitalization expected partly in Q4 FY26 and remainder by FY27-FY28.
💰 Fundraising & Capital Structure
- →India Pesticides Limited has taken a term loan of around INR 27 crores at an 8% interest rate for its new 100% subsidiary.
- →The company’s blended cost of funds for working capital is approximately 7.2% to 7.3%, with some short-term funds borrowed against FDR at 50 basis points over FDR.
- →The current credit rating is A+, with the next review due in September.
- →Capex plans for FY27 are INR 45 crores for the standalone entity and INR 90 crores for the subsidiary, mostly funded through internal accruals.
- →A small loan may be taken by the 100% subsidiary to support the capex.
- →There is no indication of any immediate equity fundraising; the company prefers internal accruals and minimal debt to fund expansions.
📋 Order Book & Pipeline
Key Metrics
Continue your research
What India Pesticides's management said in earlier quarters
Others in Fertilizers & Agrochemicals this season
- Indogulf Cropsci (Q4 FY26)
Successful single order in Venezuela contributing approximately INR 4 crores in revenue, indicating active export orders. Key concall takeaways from Indogulf…
- Rallis India (Q4 FY26)
Crop Protection B2C business growth excluding Soil & Plant Health (SPH) will be marginally positive to low single digit; SPH segment grew robustly at 27%. Key…
- Punjab Chemicals (Q4 FY26)
Overall volume growth in FY '26 was around 14%, primarily driven by new products. Key concall takeaways from Punjab Chemicals & Crop Protection Ltd's Q4 FY26…
- Krishana Phosch. (Q4 FY26)
The Company has recently completed a significant capacity expansion: NPK/DAP capacity increased by 50% to 495,000 MTPA, SSP capacity at 120,000 MTPA, totaling…
Frequently Asked Questions
What were India Pesticides Ltd Q4 FY26 results?
India Pesticides Limited aims to achieve INR 3,000 crores revenue by March 2031. India Pesticides expects revenue growth of 15-20% for the current financial year, maintaining earlier guidance.
What is India Pesticides Ltd share price analysis?
India Pesticides Ltd currently shows a neutral. The stock trades at a P/E of 15.0 with a market cap of ₹1,618 Cr. Investors should review the full earnings analysis for detailed insights.
Is India Pesticides Ltd planning capital expenditure?
India Pesticides has a capex budget of INR 45 crores for FY27 for the standalone entity and INR 90 crores for its 100% subsidiary, primarily funded through internal accruals.
Keep India Pesticides Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.